Histogenics (NASDAQ: HSGX) and BioDelivery Sciences International (NASDAQ:BDSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Histogenics and BioDelivery Sciences International’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Histogenics N/A N/A -$16.20 million ($0.22) -9.32
BioDelivery Sciences International $15.55 million 10.60 -$67.13 million ($0.19) -15.53

Histogenics has higher earnings, but lower revenue than BioDelivery Sciences International. BioDelivery Sciences International is trading at a lower price-to-earnings ratio than Histogenics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Histogenics and BioDelivery Sciences International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Histogenics N/A -658.91% -106.38%
BioDelivery Sciences International 10.40% 33.83% 6.43%

Analyst Ratings

This is a breakdown of current recommendations for Histogenics and BioDelivery Sciences International, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Histogenics 0 0 2 0 3.00
BioDelivery Sciences International 0 1 5 0 2.83

Histogenics presently has a consensus target price of $4.00, indicating a potential upside of 95.12%. BioDelivery Sciences International has a consensus target price of $4.50, indicating a potential upside of 52.54%. Given Histogenics’ stronger consensus rating and higher probable upside, research analysts clearly believe Histogenics is more favorable than BioDelivery Sciences International.

Insider and Institutional Ownership

45.0% of Histogenics shares are held by institutional investors. Comparatively, 44.1% of BioDelivery Sciences International shares are held by institutional investors. 23.8% of Histogenics shares are held by company insiders. Comparatively, 9.0% of BioDelivery Sciences International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Histogenics Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.